ストックスクリーナーアプリを入手
72.11
1.02%
0.73
前日終値:
$71.38
開ける：
$71.66
24時間の取引高:
1.30M
Relative Volume:
0.72
時価総額：
$13.96B
収益：
$4.08B
当期純損益:
$32.48M
株価収益率:
515.07
EPS:
0.14
ネットキャッシュフロー:
$16.80M
1週間 パフォーマンス:
+2.40%
1か月 パフォーマンス:
-1.85%
6か月 パフォーマンス:
+12.41%
1年 パフォーマンス:
+19.53%
1日の値動き範囲:
$71.50
$72.97
1週間の範囲:
$69.75
$72.97
52週間の値動き範囲:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
INCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
72.11 | 13.96B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Lobbying Update: $350,000 of INCYTE CORPORATION lobbying was just disclosed - Nasdaq
Incyte Corp. partners with Genesis Therapeutics to use AI for drug discovery - The Business Journals
Incyte and Genesis go boldly into AI-focused research - The Pharma Letter
Incyte joins the group getting guidance from AI’s Genesis - BioWorld Online
Incyte Secures Exclusive Rights In $30Mln AI Collaboration With Genesis Therapeutics - Nasdaq
Incyte partners with Genesis to discover new small molecule drugs - Investing.com
AI Meets Drug Discovery: Inside Incyte's $620M Genesis DealWill This Transform Pharma R&D? - StockTitan
Incyte to Present at Upcoming March 2025 Investor Conferences - BioSpace
Exclusive Healthcare Investor Access: Incyte's Double Conference Reveal Coming in March - StockTitan
Are Wall Street Analysts Bullish On Incyte Stock? - Barchart
Incyte's SWOT analysis: stock prospects amid patent cliff and pipeline potential - Investing.com
Are Wall Street Analysts Bullish on Incyte Stock? - Nasdaq
Incyte corp EVP Steven Stein sells shares worth $897,866 - MSN
Incyte jumps amid takeover speculation - MSN
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
Incyte (NASDAQ:INCY) Stock Rating Lowered by StockNews.com - MarketBeat
Incyte (NASDAQ:INCY) Price Target Raised to $77.00 at Stifel Nicolaus - MarketBeat
Incyte outlines 2025 milestones with projected $1B in incremental revenue contributions - MSN
abrdn plc Cuts Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte (NASDAQ:INCY) Trading Down 8.5% Following Weak Earnings - MarketBeat
State of Alaska Department of Revenue Has $1.26 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Citigroup Issues Pessimistic Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Stifel raises Incyte stock price target to $77 from $75 - MSN
Sumitomo Mitsui Trust Group Inc. Cuts Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte (NASDAQ:INCY) Issues Earnings Results - MarketBeat
Incyte stock falls 6% amid Q4 earnings, 2025 forecast - MSN
Incyte stock price target raised to $88 at TD Cowen - MSN
Cambiar Investors LLC Has $9.65 Million Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
JPMorgan Adjusts Incyte Price Target to $70 From $75, Maintains Neutral Rating -February 12, 2025 at 10:29 am EST - Marketscreener.com
Incyte backs out of immuno-oncology pact with Agenus - PharmaLive
Reevaluating Incyte Corporation After Earnings (Technical Analysis) - Seeking Alpha
Incyte Backs Out of Immuno-Oncology Pact With Agenus - BioSpace
Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus.com
Incyte Earnings: Strong Opzelura Sales; Focus on Expanding Portfolio Amid Jakafi Patent Expiration - Morningstar
Upcoming Patent Loss of Jakafi Highlights Portfolio Risks; Downgrading Incyte's Moat to None - Morningstar
Incyte's Revenue Beats Estimates Thanks To Jakafi And Opzelura - Finimize
Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics - MSN
Incyte (INCY) Stock Drops Amid Slower Growth Outlook - GuruFocus.com
Royal Bank of Canada Has Lowered Expectations for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
RBC cuts Incyte stock price target to $68 from $70 - Investing.com
Incyte Corporation (NASDAQ:INCY) Q4 2024 Earnings Call Transcript - Insider Monkey
What Analysts Are Saying About Incyte Stock - Benzinga
Citi cuts Incyte stock price target to $88, maintains buy rating - MSN
Jefferies Adjusts Price Target on Incyte to $81 From $84, Maintains Buy Rating -February 11, 2025 at 07:18 am EST - Marketscreener.com
Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Incyte’s Strong 2024 Financial Performance and Promising Outlook - MSN
Applovin, Incyte, Onsemi - TradingView
Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook - Yahoo Finance
Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook By GuruFocus - Investing.com Canada
Why Incyte (INCY) Shares Are Plunging Today - The Globe and Mail
Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):